Arcturus Therapeutics Holdings Inc
ARCT
查看详细走势图
6.590USD
+0.060+0.92%
收盘 12/22, 16:00（美东）报价延迟15分钟
179.48M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.92%
5天
-11.66%
1月
+5.27%
6月
-46.38%
今年开始到现在
-61.17%
1年
-57.43%
查看详细走势图
TradingKey Arcturus Therapeutics Holdings Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Arcturus Therapeutics Holdings Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名70/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价32.12。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Arcturus Therapeutics Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
11
位分析师
买入
评级
32.125
目标均价
+331.21%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Arcturus Therapeutics Holdings Inc亮点
亮点风险
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
估值合理
公司最新PE估值-2.65，处于3年历史合理位
机构加仓
最新机构持股24.41M股，环比增加0.27%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值11.86K
活跃度增加
近期活跃度增加，过去20天平均换手率0.56
Arcturus Therapeutics Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Arcturus Therapeutics Holdings Inc简介
Arcturus Therapeutics Holdings Inc. is a commercial mRNA medicines and vaccines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. The Company with enabling technologies, including LUNAR lipid-mediated delivery, STARR mRNA technology (sa-mRNA) and mRNA drug substances along with drug product manufacturing. It has developed KOSTAIVE, a self-amplifying messenger RNA (sa-mRNA) COVID vaccine. The Company’s pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The Company's versatile RNA therapeutics platforms can be applied to multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics.
公司代码ARCT
公司Arcturus Therapeutics Holdings Inc
CEOPayne (Joseph E)
网址https://arcturusrx.com/
常见问题
Arcturus Therapeutics Holdings Inc(ARCT)的当前股价是多少？
Arcturus Therapeutics Holdings Inc(ARCT)的当前股价是 6.590。
Arcturus Therapeutics Holdings Inc的股票代码是什么？
Arcturus Therapeutics Holdings Inc的股票代码是ARCT。
Arcturus Therapeutics Holdings Inc股票的52周最高点是多少？
Arcturus Therapeutics Holdings Inc股票的52周最高点是24.170。
Arcturus Therapeutics Holdings Inc股票的52周最低点是多少？
Arcturus Therapeutics Holdings Inc股票的52周最低点是5.850。
Arcturus Therapeutics Holdings Inc的市值是多少？
Arcturus Therapeutics Holdings Inc的市值是179.48M。
Arcturus Therapeutics Holdings Inc的净利润是多少？
Arcturus Therapeutics Holdings Inc的净利润为-80.94M。
现在Arcturus Therapeutics Holdings Inc(ARCT)的股票是买入、持有还是卖出？
根据分析师评级，Arcturus Therapeutics Holdings Inc(ARCT)的总体评级为买入，目标价格为32.125。
Arcturus Therapeutics Holdings Inc(ARCT)股票的每股收益（EPS TTM）是多少
Arcturus Therapeutics Holdings Inc(ARCT)股票的每股收益（EPS TTM）是-2.461。
相关品种
